Arcadia Biosciences files S-8 filing for Arcadia Biosciences stock

Published on 10/21/2026 at 00:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The S-8 covers employee plans. Nasdaq's USD 2.50 million equity threshold now shapes Arcadia Biosciences stock.

Filing and reporting dates

Arcadia Biosciences filed its employee-plan S-8 on September 30, 2026.
Second-quarter 2026 revenue was USD 1.443 million against a USD 6.266 million net loss.
Arcadia Biosciences is estimated to report third-quarter 2026 results on November 5, 2026.

RKDA, US0390143032, Illustration mit AI erstellt.

Arcadia Biosciences filed a Form S-8 for employee benefit plans on September 30, 2026, according to the SEC. The filing arrives as Nasdaq listing compliance and financing capacity remain the central questions for Arcadia Biosciences stock.

Employee plan filing adds context

The S-8 is a registration statement for securities offered through employee benefit plans. The filing date gives investors a concrete marker for the company's recent capital-markets activity, while the broader listing issue centers on equity and bid-price requirements.

Tickeron reported that Arcadia's stockholders' equity was USD 633,000 as of June 30, 2026, compared with Nasdaq's USD 2.50 million minimum threshold. The same report said the company faced an October 15, 2026 deadline to submit a compliance plan.

Three dates frame the story

On June 12, 2026, Arcadia closed a private placement worth USD 4.00 million, as listed by MarketBeat. On September 10, 2026, shareholders approved a reverse-split authorization covering ratios from 1-for-2 to 1-for-10, according to Tickeron. On September 30, 2026, the company filed the S-8 registration statement with the SEC.

What does the equity test mean?

The numerical gap is the key risk marker: USD 633,000 of equity stood against a USD 2.50 million requirement. Arcadia's latest reported operating figures add pressure to that balance-sheet question. For the second quarter of 2026, MarketBeat reported revenue of USD 1.443 million, below the USD 1.90 million consensus estimate, and a loss per share of USD 2.09 versus a USD 0.56 estimate.

Next reporting date is November 5

MarketBeat lists November 5, 2026 as the estimated date for Arcadia's third-quarter 2026 results. That release should provide the next quantified update on revenue, losses and the company's response to Nasdaq's equity test.

Home-market quote remains volatile

Arcadia Biosciences was last at USD 0.15 on Nasdaq on October 20, 2026 at 4:00 p.m. ET, while its market capitalization was USD 0.2 million as of October 20, 2026. The 52-week range was USD 0.11 to USD 4.78 on that date.